OptimizeRx Corporation

NASDAQ:OPRX

Medical - Healthcare Information Services

Healthcare
$7.31 -0.98%

-$0.05 today

Market cap
$138.21M
Beta
1.10
P/E (TTM)
13.8
EPS (TTM)
$0.36
52W Low $4.57High $22.25

Volume 0.18M

Average 0.47M

OPRX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

OptimizeRx CorporationNASDAQ: OPRX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $5.98M fell 30.4% year over year, behind the -1.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 26.6% from the prior quarter. Over 3 fiscal years it compounded at +19.6% a year.

Context

  • Cost of revenue amounted to 36.7% of revenue in FY2025, up 1.2 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -30.4% toward the trailing-twelve-month pace of -1.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.98M-26.6% QoQ
Last fiscal yearDec 2025
$40.16M+22.6% YoY
LTMMar 2026
$33.23M-1.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.4%——
1 year+22.6%——
3-year CAGR+19.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
40.16M USD
Year-over-year change
+22.6%
4-year CAGR
+11.9%

Cost of Revenue vs competitors

How OPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.8% is the 6th highest of 9, against a peer median of +3.8%.
  • Cost of revenue amounts to 31.0% of revenue for OPRX, versus a peer median of 35.4%.
OPRX Competitors
Cost of Revenue for OPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TBRGTruBridge, Inc.LTM Mar 2026$168.68M USD+1.4%-0.7%48.8%
DHDefinitive Healthcare Corp.LTM Mar 2026$65.42M USD+14.6%+11.0%27.5%
NRCNational Research CorporationLTM Mar 2026$61.21M USD+6.1%+1.7%44.2%
OPRXOptimizeRx CorporationLTM Mar 2026$33.23M USD-1.8%+19.6%31.0%
SLPSimulations Plus, Inc.LTM Feb 2026$30.63M USD-12.8%+44.9%38.0%
RXSTRxSight, Inc.LTM Mar 2026$29.3M USD-43.5%+4.4%23.0%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$26.56M USD+23.9%+21.8%32.7%
NAKANakamoto Inc.LTM Mar 2026$18.66M USD+353.9%+317.5%476.0%
SPOKSpok Holdings, Inc.LTM Mar 2026$17.62M USD-64.5%-20.7%12.9%
DRUGBright Minds Biosciences Inc.LTM Mar 2026CA$20.13K CAD———
Peer median (excluding OPRX) —+3.8%+7.7%35.4%

Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.29M62.45M71.52M92.13M109.43M
Cost of Revenue25.65M23.48M28.62M32.75M40.16M
Gross Profit35.64M38.97M42.9M59.38M69.27M
Gross Margin58.1%62.4%60.0%64.5%63.3%
Research & Development00000
Selling, General & Admin33.19M49.24M58.02M61.27M50.25M
Operating Expenses35.28M51.26M69.3M73.08M57.21M
Depreciation & Amortization1.97M2.02M2.4M4.33M4.33M
EBITDA2.34M(9.42M)(21.31M)(8.9M)16.57M
EBITDA Margin3.8%-15.1%-29.8%-9.7%15.1%
Operating Income361.1K(12.29M)(26.4M)(13.71M)12.06M
Operating Margin0.6%-19.7%-36.9%-14.9%11.0%
Interest Income16.98K852.3K2.19M329K353K
Interest Expense001.45M6.16M5.29M
Other Income / Expenses16.98K852.3K1.24M(5.68M)(5.11M)
Income Before Tax378.08K(11.44M)(25.16M)(19.39M)6.95M
Pre-Tax Margin0.6%-18.3%-35.2%-21.0%6.4%
Income Tax Expense00(7.6M)725K1.82M
Net Income378.08K(11.44M)(17.57M)(20.11M)5.13M
Net Margin0.6%-18.3%-24.6%-21.8%4.7%
EPS (Basic)0.02(0.64)(1.03)(1.10)0.28
EPS (Diluted)0.02(0.64)(1.03)(1.10)0.27
Weighted Avg Shares17.23M17.78M17.12M18.29M18.56M
Weighted Avg Shares (Diluted)17.69M17.78M17.12M18.29M19M

OptimizeRx Corporation

NASDAQ:OPRX

Intrinsic Alpha fair value

Locked

Current Price

$7.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.